Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

As a leading provider of direct-to-patient and direct-to-physician marketing solutions, Health Monitor Network is once again expanding its senior leadership team during this period of strong growth.

In his welcome remarks at the October 7 conference, Tim Hunt, CEO of the Alliance for Regenerative ... percentage points (see more details here) AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical ...

Abbvie, based in North Chicago ... and creative work of the EvolveImmune team," said Dr. Stephen Bloch, CEO of EvolveImmune. EvolveImmune Therapeutics Inc., based at 23 Business Park Drive ...

which is $1.3 billion ahead of AbbVie’s initial expectations. Skyrizi’s impressive clinical results have allowed it to achieve in-play biologic share leadership in 30 key countries in ...

AbbVie announced Monday that it is buying Aliada ... Check out those stories and more pharmaceutical news highlights from this week. CEO of Eli Lilly and Company David Ricks speaks at the Economic ...

SpaceX CEO Elon Musk heaped praise on Boeing Co.’s BA current CEO earlier this week after slamming its former CEO Dave Calhoun for the company’s many hardships throughout the year. What ...

dividend-frequency { font-size: 12px; color: #6c757d; } Through a meticulous analysis of AbbVie, we can observe the following trends: A Price to Earnings ratio of 70.21 significantly below the ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

AbbVie is entering into a collaboration and option-to-license deal with EvolveImmune Therapeutics to develop biologics for multiple oncology targets. Connecticut-based EvolveImmune, which develops ...

Richard Gonzalez listed T-cell engagers as a modality in which AbbVie had a high level of interest before he stepped down as CEO of the company. Responding to an analyst question about AbbVie’s ...